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 君子学以聚之，问以辩之，宽以居之，仁以行之。 
                                                                  ——《周易·乾卦·文言》
  
ABSTRACT 
Microglia are innate immune cells that reside in the central nervous system (CNS). Their 
activities are critical for ensuring the correct microenvironment for brain development and for 
maintaining homeostasis in the brain after birth. However, during the lifetime, the neuronal 
and the glial cells in the brain suffer from multiple challenges that require microglia to react 
and to execute different functions. Under diverse pathological conditions, polarized microglia 
have detrimental effects by either promoting neuronal death in neurodegenerative diseases, or 
shaping the microenvironment to enhance brain tumor growth and invasiveness. Although 
microglia contribute to the maintenance of brain homeostasis and the pathogenesis of brain 
tumors, the molecular mechanisms behind their polarization towards selective phenotypes 
remains elusive. 
In the first study, we describe a novel molecular mechanism employed by glioma cells to 
polarize microglia towards a tumor-supportive phenotype. We demonstrate that decreased 
basal caspase-3 activity in microglia is a necessary condition for their polarization into a 
tumor-supportive phenotype. We reveal that this process relies on the inhibition of microglial 
thioredoxin-2 denitrosylation activity, which in turn leads to increased S-nitrosylation of 
caspase-3. Furthermore, we demonstrate that microglial thioredoxin-2 becomes inactive due 
to nitric oxide (NO) originating from the glioma nitric oxide synthase-2 (NOS2) 
activity.  Using a syngeneic glioma tumor model in immunocompetent mice, and through 
different strategies including the generation of a Casp3
flox/flox
Cx3cr1
CreERT2
 mouse model, we 
validated that interfering with this glioma-microglia signaling pathway impacted on the 
recruitment of microglia towards the tumor and also the tumor growth. 
Our current findings, together with previous report from our lab, uncover a central role for 
distinct caspase-3-dependent signaling pathways in the regulation of different microglia 
phenotypes. Previously it was established that the sequential activation of caspase-8 and 
caspase-3/7 is of importance for the pro-inflammatory polarization of microglia. In the 
present study, we demonstrate a role for thioredoxin-2 mediated repression of caspase-3 in 
promoting a tumor-supportive phenotype in microglia. Mechanisms promoting a tumor-
supportive phenotype in immune cells are of extraordinary importance, given the strong 
correlation between this phenotype and tumor malignancy. Our research work suggests that 
caspase-3 may function as a rheostat which modulates microglial polarization states in 
response to various stimuli. More specifically, we show that highly elevated activity of 
caspase-3 causes cell death, while moderate induced activity and reduced basal activity of 
caspase-3 regulates the pro-inflammatory and the tumor-supportive microglial polarization 
states, respectively.  
Brain injury is commonly followed by neuroinflammation, and microglia are critical cellular 
elements of the brain mediating this process. In the second study, neural stem cells (NSCs) 
were exposed to conditioned medium originating from non-stimulated microglia, or 
stimulated microglia exhibiting pro- or anti-inflammatory phenotype. We found that NSCs 
grown in conditioned medium collected from anti-inflammatory microglia had better 
survival, enhanced migration and lower astrocytic differentiation compared to NSCs kept in 
conditioned medium deriving from pro-inflammatory microglia. This study demonstrates that 
pro- and anti-inflammatory microglia regulate NSCs functions differentially, and they induce 
chemokine CCL2 expression in differentiated NSCs. 
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1 INTRODUCTION 
 
1.1 MICROGLIA 
Microglia are innate immune cells, which reside in the central nervous system (CNS). They 
are distributed throughout the brain parenchyma and they constitute about 5-10% of the entire 
cell population in the adult brain (Turrin and Rivest, 2006). The microglial population serves 
as the key regulator of immune response in the CNS. Historically, microglia were discovered 
and characterized in the early 20
th
 century (Del Río Hortega, 1919). However, the functional 
profiles of microglia have remained veiled for a long time since their discovery. The vast 
majority of microglial research has been emerging only since two decades ago and the 
research field is approaching a dynamic stage nowadays.  
Microglia reside in close proximity to other types of cells in the brain. Of note, they directly 
interact with neuronal cells and other glial cells during development of the healthy brain 
(Frost and Schafer, 2016; Nayak et al., 2014). After birth, microglial cells contribute to the 
homeostasis in the mature brain. Their functions are partially understood in physiological 
conditions, while their central roles in the development of pathological events are well 
demonstrated in brain disorders including ischemic brain injury, neurodegenerative diseases 
and brain tumors (Perry et al., 2010; Watters et al., 2005; Weinstein et al., 2010). In response 
to various microenvironmental cues, microglia can promote neuronal cell death or tumor cell 
growth during disease progression, but they can also be beneficial to the brain parenchyma by 
defending invading pathogens and by facilitating tissue recovery process following brain 
damages. Thus, microglia has been an ideal target for therapeutic interventions in brain 
diseases.   
1.1.1 THE ORIGIN AND HOMEOSTASIS OF MICROGLIA 
The origin of microglia is different from other brain cell types. Therefore, they are considered 
as unique and specialized tissue macrophages. Recent RNA-sequencing transcriptome studies 
identified the molecular signatures of unstimulated microglia, which distinctly separate them 
from other CNS cells, from peripheral myeloid cells, as well as from microglia deriving from 
mouse model with neurodegenerative disease (Chiu et al., 2013; Gautier et al., 2012; Zhang 
et al., 2014). Nevertheless, microglia share certain characteristics with other myeloid cell 
types, for instance surface markers and phagocytic activity.  
However, the precise origin, cell lineage and mechanisms underlying homeostasis of 
microglia has been under debate for a long time (Ling and Wong, 1993). Alliot and 
colleagues proposed that microglia progenitors derive from the yolk sac (YS) and they appear 
in the murine brain rudiment since early embryonic stage. Furthermore, they observed that 
the number of microglia increased within the first two postnatal weeks (Alliot et al., 1999; 
Alliot et al., 1991). Recent fate mapping analysis performed on mice conclusively confirmed 
that the primitive YS macrophages contribute predominately to the resident microglia 
population (Ginhoux et al., 2010). Currently it is accepted that the production of 
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hematopoietic stem cells (HSCs) initially takes place in murine embryonic aorta-gonad-
mesonephros (AGM) region, event that occurs shortly after generation of primitive 
macrophages in YS. Subsequently, the HSCs will give rise to all the myeloid cells and 
lymphoid cells later during development. (Cumano and Godin, 2007). Before the 
establishment of blood-brain barrier (BBB), the YS-primitive macrophages colonize the 
embryonic neuroepithelium where they generate microglia. Thereafter, embryonic microglia 
invade the CNS and colonize all the regions in there.  
Notably, microglia have a long lifespan and they renew themselves by local proliferation in 
the CNS since late embryonic stage of development (Ajami et al., 2007; Lawson et al., 1992). 
Nevertheless, under certain pathological conditions, bone marrow-derived cell populations 
can penetrate the BBB and undergo differentiation to macrophage/microglia (Malm et al., 
2005; Simard et al., 2006). In particular, when the BBB is injured the peripheral monocytes 
can migrate to the diseased brain, in reaction to inflammations (Ajami et al., 2011). Several 
molecular factors regulating the homeostasis of microglia have been identified. The absence 
of colony-stimulating factor-1 (CSF-1) or of the corresponding receptor CSF-1R and 
interleukin-34 (IL-34) results in a substantial reduction of microglia numbers in the mouse 
brain (Ginhoux et al., 2010; Wang et al., 2012; Wegiel et al., 1998). In addition, one recent 
study revealed that the steady number of microglia is maintained by balanced microglial 
proliferation and cell death in the adult brain during the lifetime, and CSF-1R is necessary for 
controlling this process in microglial homeostasis (Askew et al., 2017). Moreover, the PU.1 
transcription factor and its interacting partner interferon regulatory factor-8 (IRF-8) are 
important for microglial development. Deficiency of PU.1 or IRF-8 leads to decrease of 
microglial density in the mouse brain (Kierdorf et al., 2013).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
1.1.2 THE ROLE OF MICROGLIA IN BRAIN PHYSIOLOGY  
Our understanding of microglial functions are primarily based on their roles in pathological 
conditions. Their physiological functions have been partly characterized by developmental 
biologists, although their functions in adult brain remain elusive. Microglia maintain 
homeostasis in the brain under physiological conditions, whereas they conduct phagocytosis 
and mediate neuroinflammation, tissue repair and immune responses in reaction to brain 
injury (Mallat et al., 2005; Wynn et al., 2013). Microglial cells are never resting, but 
constantly moving their ramified processes to survey and scan their surroundings (Davalos et 
al., 2005; Nimmerjahn et al., 2005). In the healthy brain, microglial cells are able to rapidly 
detect any disturbance in the brain parenchyma. Moreover, microglia are well known for their 
capacity of engulfing apoptotic cells in the developing brain (Ferrer et al., 1990). But 
microglial functions go beyond of their phagocytic capacity as the cleaners of the brain. 
Interestingly, microglia can induce apoptosis on the target cells which they will engulf later 
on. It has been shown during embryonic development that microglia can release nerve growth 
factor (NGF) or reactive oxygen species (ROS) to induce death of neurons (Frade and Barde, 
1998; Wakselman et al., 2008). Furthermore, microglia phagocytose non-apoptotic neural 
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precursor cells in order to regulate their population size in the developing brain, but 
microglial ablation or inhibition abrogates this regulation (Cunningham et al., 2013).  
Microglia are not only capable of regulating neuronal apoptosis during development but also 
supporting cell survival and proliferation. Several studies on microglial conditioned medium 
have supported that microglia release soluble trophic factors to increase neuronal 
proliferation and promote neuronal differentiation in vitro (Jonakait et al., 1996; Morgan et 
al., 2004; Nagata et al., 1993). In addition, one recent in vivo investigation demonstrated that 
microglia-derived insulin growth factor-1 (IGF-1) is necessary for cortical neurons survival 
during early postnatal development (Ueno et al., 2013).  
Another study reported the enhancement of both neurogenesis and oligodendrogenesis 
requires activated microglia-released pro-inflammatory cytokines (Shigemoto-Mogami et al., 
2014). Growing evidences extend our understanding of microglia’s functions as they can also 
promote astrogliogenesis from neural stem cells (NSCs) and that effect is impaired in the 
mice lacking resident microglia  (Antony et al., 2011; Nakanishi et al., 2007; Zhu et al., 
2008). Hence, microglia control the integrity and activity of the developing brain by 
regulating CNS cell death, survival, proliferation and differentiation. Furthermore, microglia 
regulate the construction of synaptic network in prenatal stage, and they refine the network in 
an activity dependent fashion to eliminate overproduced or incorrect synaptic contacts and to 
support the formation of necessary new ones in postnatal stage (Parkhurst et al., 2013; 
Schafer et al., 2012; Stevens et al., 2007; Wake et al., 2009). 
1.1.3 THE ROLE OF MICROGLIA IN TUMOR BIOLOGY 
As the CNS resident immune cells, microglia essentially protect the brain from damages. 
Once exposed to pathogens, microglia polarize to a pro-inflammatory phenotype and produce 
a wide variety of inflammatory factors to defend against the infections, followed by 
elimination of pathogens and debris (Mariani and Kielian, 2009). The pro-inflammatory 
microglia possess potent anti-tumor properties, but they might become immunosuppressive 
cells in the course of glioma progression (Wei et al., 2013). An early study on human 
glioblastoma specimens reported infiltrating microglia/macrophages account for a significant 
population in tumor mass ranging from 8% to 78% (Morantz et al., 1979). Likewise, CD68
+
 
microglia/macrophages are found in the majority of low grade astrocytomas (Yang et al., 
2011). The microglia/macrophages infiltration in glioma correlates with malignancy grade 
and high vascularity (Nishie et al., 1999). In addition, it has been shown that the percentage 
of microglia/macrophages displaying anti-inflammatory properties correlates with the grade 
of human glioma (Komohara et al., 2008). Hence, accumulation of microglia/macrophages in 
gliomas indicates that they do not only skip tumor surveillance, but they also play a role in 
promoting tumor progression.  
Since microglia and macrophages share many surface markers, it is difficult to differentiate 
them through conventional approaches. Therefore, it is not clear which cell type plays the 
major role over the other one in glioma biology. A recent study on chimeric mice 
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demonstrated that the monocytes-derived macrophages start to infiltrate the brain only in the 
late stage of glioma progression, representing 25% of all glioma-infiltrating myeloid cells in 
mice (Muller et al., 2015). In this study, mice were subjected to total body irradiation or 
head-protected irradiation, followed by transplantation of GFP
+
 bone marrow cells. Thereby, 
the naïve monocytes were damaged and replaced by their GFP
+
 counterparts. At the same 
time, the brain intrinsic microglia and the blood-brain barrier (BBB) were preserved in the 
mice with head-protected irradiation, preventing non-physiological infiltration of peripheral 
monocytes in healthy brain. Subsequently, the GL261 glioma cells were intracranial 
inoculated in chimeric mice. It was shown the GFP
+ 
monocytes/macrophages did not 
infiltrate tumor mass until 21 days post tumor engraftment. Moreover, this study revealed that 
glioma-associated microglia are capable to increase the expression of CD45, comprising a 
portion of CD45
high
 cells which are commonly identified as macrophages (Muller et al., 
2015). High grade gliomas are characterized by abnormal vascularity. The selective depletion 
of microglia results in 50% reduction of blood vessels density in experimental GL261 glioma, 
which is similar to the consequence from ablation of all CD11b
+
 myeloid cells, implying 
microglia play a predominant role in promoting glioma angiogenesis (Brandenburg et al., 
2016). 
Different experimental approaches have been utilized to explore the role of microglia in 
glioma biology. One in vitro study reported that microglial cells and microglia-conditioned 
medium significantly support and promote GL261 glioma cells migration, whereas 
oligodendroglia and endothelial cells show only weak promoting effect on motility of glioma 
cells (Bettinger et al., 2002). Similarly, it has been shown that murine tumor infiltrating 
microglia/macrophages can promote CD133
+
 glioma stem cells invasiveness through a 
transforming growth factor-β (TGF-β) signaling axis (Ye et al., 2012). In organotypic brain 
slice cultures, the invasiveness of glioma cells are substantially reduced upon selective 
depletion of endogenous microglia by treating the slices with liposomes harboring clodronate 
(Markovic et al., 2005). Also the eradication of intrinsic microglia by ganciclovir treatment 
led to a reduction in tumor volume in a glioma mouse model (Brandenburg et al., 2016). 
Taken together, these data demonstrate that microglia are central in glioma progression, 
particularly in promoting glioma growth and invasion.  
Microglia promote glioma invasion through degradation of the extracellular matrix (ECM) by 
activating matrix metalloprotease (MMP) in a cooperative manner. Glioma cells produce 
inactive pro-MMP2 which needs further cleavage to become active. Once in contact with 
glioma cells, microglia enhance MMP14 (MT1-MMP) expression. Subsequently, microglial 
MMP14 cleaves glioma pro-MMP2 enabling it become into active MMP2. The stepwise 
activation of MMPs is necessary for glioma cells, since overexpression of MMP14 in glioma 
cells per se induce cell death (Markovic et al., 2009). 
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Figure 1. Cross-talk between microglia and glioma cells.  
Glioma cells recruit and induce microglia polarization towards a tumor-supportive phenotype 
through cell-cell communications (Figure 1). Several paracrine loops have been identified 
underlying these processes. For instance, human glioma cells secrete chemokine (C-C motif) 
ligand 2 (CCL2) that attract microglia towards the tumor. At the same time, they also 
stimulate the CCL2 receptor (CCR2) on microglia which in turn produce IL-6 to promote 
glioma invasion (Zhang et al., 2012). Another report demonstrated that glioma cells 
constitutively produce CSF-1 which is a known chemoattractant factor. Glioma CSF-1 
activates microglial CSF-1 receptor (CSF-1R) signaling, which triggers the release of 
epidermal growth factor (EGF). Next, microglial EGF acts on glioma EGF receptor (EGFR) 
leading to increase of glioma proliferation and invasiveness (Coniglio et al., 2012).  
In contrast, one recent study showed that microglia still possess the anti-tumor ability when in 
contact with glioma. In a coculture setting, the proliferation of glioma stem cells from 
glioblastoma patient was mitigated by naïve microglia from non-glioma epilepsy brain, but 
not curbed by the glioma-associated microglia. Furthermore, the cytokine profiling revealed 
pro-inflammatory factors (e.g. CCL2, IL-8) were released by naïve microglia but not by 
glioma-associated microglia (Sarkar et al., 2014). However, the timing at which microglia are 
compromised and switched to the tumor-supportive phenotype during glioma progression 
remains unclear. Although no conclusive findings are available, most likely microglial cells 
skew their functions towards tumor-supporting in the early period upon exposure to gliomas.   
1.1.4 MICROGLIA POLARIZATION 
In physiological conditions, microglia are surveying cells that inspect the brain parenchyma 
through moving their numerous long ramified processes (Nimmerjahn et al., 2005). But 
under pathological conditions, microglia undergo morphological changes: they display fewer 
and shorter ramified process, and eventually adopt an amoeboid phenotype. Along with the 
morphological changes, microglia alter their gene expression profiles and motility, leading to 
changes of their activities and functions according to distinct conditions (Hanisch, 2002; 
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Henry et al., 2009; Rawji et al., 2016). Microglia possess high sensitivity and great plasticity, 
and differentially react to the microenvironmental cues accompanied by polarization to 
diverse states (Hanisch and Kettenmann, 2007). Microglia polarization is a progressive and 
dynamic process which is dependent on stimuli under different conditions.  
Over time, one useful concept facilitating our understanding of microglia polarization has 
been the M1/M2 model. In this model, microglia adopt a pro-inflammatory phenotype, so-
called M1, upon stimulation of lipopolysaccharides (LPS) or interferon-γ (IFN-γ) in vitro, 
resulting in production of inflammatory factors including IL-1β, tumor necrosis factor-α 
(TNF-α) and nitric oxide (NO). On the other hand, microglia polarize to an anti-inflammatory 
phenotype, referred to as M2, when stimulated by IL-4 or IL-13, leading to production of 
factors like IL-10, arginases-1 that promote tissues remodeling. It is worthy to notice that this 
is a simplified dichotomy model reflecting in vitro experimental settings, and also microglia 
are assumed to expose to limited number of stimuli. However, recent investigations indicate 
that this model fails to describe the actual diverse polarization states in vivo (Martinez and 
Gordon, 2014; Ransohoff, 2016). For instance, the proposed M2 phenotype and its subtypes 
(M2a, M2b and M2c) cannot define exclusively the tumor-associated microglia (Szulzewsky 
et al., 2015).  
The notion of microglia M1/M2 classification was inspired by macrophage polarization 
paradigm (Mills et al., 2000). However, the M1/M2 terms do not faithful reflect macrophage 
activation and polarization neither (Ginhoux et al., 2016). One recent comprehensive study 
demonstrated the complex nature of macrophage activation states. In this study, human 
macrophage were exposed to 29 in vitro conditions, and subsequent transcriptome profiling 
of those macrophage revealed a multidimensional model rather than a linear spectrum model 
underlying macrophage polarization (Xue et al., 2014). Moreover, since macrophage 
activation is stimulus-dependent, it has been suggested to describe macrophage activations 
with stimulation scenarios (Murray et al., 2014). Microglia/macrophages tailor their 
polarization to a large extent in different context. Hence, it is of importance to understand the 
functions regardless of the nomenclature.  
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1.2 GLIOMAS 
Occurrences of uncontrolled abnormal cell growth in the brain inevitably initiate the 
formation of brain tumors. Primary brain tumors derive from the transformed cellular 
elements in the brain parenchyma and meninges; whilst metastatic brain tumors are the 
cancer cells spread from other parts of the body, mostly lung and breast. The latter occurs 
more frequently than the primary types (Vecht, 1998). Among all malignant primary brain 
tumors, gliomas represent the most common form and constitute 70% in adults (Ricard et al., 
2012). The most common symptoms presented by glioma patients include headache, nausea, 
seizures, focal neurological deficits and raised intracranial pressure (Behin et al., 2003). The 
conventional treatment protocol for high-grade gliomas is surgery typically followed by 
fractionated radiation therapy and temozolomide chemotherapy aiming to remove the tumors 
as much as possible. Despite the standard treatment, the median survival of patients 
diagnosed with high-grade gliomas is less than 15 months (Stupp et al., 2005).  
1.2.1 CLASSIFICATION OF GLIOMAS 
Gliomas consist of astrocytomas, oligodendrogliomas and ependymomas which are named 
based on the type of glial cell the tumor originates from. Gliomas are graded as following: 
Grade I (pilocytic astrocytoma), Grade II (astrocytoma, oligodendroglioma and mixed 
oligoastrocytoma), Grade III (anaplastic astrocytoma, anaplastic oligodendroglioma and 
anaplastic oligoastrocytomas) and Grade IV (glioblastoma multiforme), based on the World 
Health Organization (WHO) classification (Louis et al., 2007). High-grade gliomas (Grade 
III and IV) are defined as malignant types which grow rapidly. The WHO classification is 
based on histopathological features. Grade III gliomas are featured by the presence of mitotic 
activity and nuclear atypia, and Grade IV gliomas by necrosis or microvascular proliferation. 
1.2.2 GLIOBLASTOMA MULTIFORME 
Glioblastoma multiforme (GBM) is known as the most malignant and frequently occurring 
glioma. Glioblastomas arise de novo as primary tumors or from lower grade gliomas as 
secondary tumors. Primary GBMs are detected in broad brain regions and commonly in 
patients over 50 years-old, which accounts for the majority (95%) of all cases. Secondary 
GBMs comprise the remainder (5%) of the cases and they occur in the frontal lobe and 
typically in younger patients preceded from lower grade gliomas over years (Ohgaki and 
Kleihues, 2005).  
Like other types of cancers, malignant transformation and following glioma progression 
result from the accumulation of genetic alterations, chromosome instability and unregulated 
growth factor signaling pathways (Ohgaki and Kleihues, 2007). Primary GBMs are 
characterized by loss of heterozygosity (LOH) at chromosome 10q, deletion of CDKN2 
family, mutations of tumor suppressor genes PTEN, NF1, Rb and p53, as well as 
dysregulation of signaling pathways involving phosphoinositide 3-kinase (PI3K)/Akt and 
receptor tyrosine kinase (RTK)/growth factor (Dunn et al., 2012). Cellular growth factor 
receptors like EGFR, MET receptor and platelet-derived growth factor receptor (PDGFR) are 
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commonly mutated in glioblastomas, leading to acceleration of tumor cell proliferation 
(Furnari et al., 2007). Notably, amplification of EGFR and its variant EGFRvIII are observed 
in approximately 50% of primary GBMs, but seldom in secondary GBMs or in normal tissue 
(Schlegel et al., 1994). EGFRvIII, the most commonly mutated variant of EGFR, is deficient 
for the ligand-binding domain but is constitutively activated, and has been suggested as a 
prognostic factor and therapeutic target for inhibitors and antibody treatment 
(Sathornsumetee et al., 2007; Shinojima et al., 2003).  
On the other hand, younger patients with lower-grade gliomas often develop IDH1 mutations 
in early stage of tumorigenesis. Subsequently, they acquire multiple other gene mutations like 
p53 and Rb, and also overexpress PDGFR, and they progress to higher-grade gliomas or 
directly to secondary GBMs over a period of years. The mutant isocitrate dehydrogenase 1 
(IDH1) is associated with an improved prognosis for glioma patients (Dimitrov et al., 2015). 
In human cells, there are three IDH isoforms including cytosolic IDH1 and mitochondrial 
IDH2 and IDH3. IDH1 and IDH2 normally convert isocitrate to α-ketoglutarate (α-KG), 
coupled with reduction of NADP
+
. However, mutant IDH1/IDH2 catalyzes the reduction of 
α-KG to R-2-hydroxyglutarate (2-HG) in a NADPH dependent manner. Interestingly, 2-HG 
has been identified as an onco-metabolite, and its excess accumulation in human leads to the 
malignant transformation and progression of gliomas (Dang et al., 2009). 
Malignant gliomas display inter-tumor heterogeneity among the group of same WHO grade 
gliomas. Glioblastomas are well known for the high invasive capability and heterogeneous 
nature. Utilizing transcriptome profiling, two landmark studies have fundamentally modified 
our view of molecular classification of glioblastomas (Phillips et al., 2006; Verhaak et al., 
2010). In total, four GBM molecular subtypes including proneural, neural, classical and 
mesenchymal were identified through comprehensive analysing of the gene expression 
patterns. The gene expression profile of GBM neural subtype were found however similar to 
that of the normal brain tissues. Despite the neural subtype, the proneural, classical and 
mesenchymal subtypes have unique genetic aberrations characterized by abnormal expression 
of genes PDGFRA/IDH1, EGFR and NF1, respectively. Interestingly, the majority of 
younger patients are classified as the proneural subtype in which mutations of IDH1 was 
almost exclusively identified. Moreover, the patients manifesting IDH1 mutations do not 
harbor PDGFRA alterations and vice versa (Verhaak et al., 2010).  
Furthermore, one recent study using a more comprehensive approach identified six distinct 
methylation groups of diffuse gliomas which are segregated into two macro-groups according 
to IDH status. More specifically, this study showed that IDH1/IDH2 mutation and IDH 
wildtype were enriched for lower grade gliomas (Grades II and III) and GBM, respectively. 
In addition, the IDH mutant group displayed genome-wide higher methylation level than the 
IDH wildtype group (Ceccarelli et al., 2016). 
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1.2.3 GLIOBLASTOMA MODELS  
Numerous approaches have been employed for developing GBM animal models. These 
models mainly include chemically induced syngeneic models, genetically engineered models 
and human cell based xenograft models. From historical perspective, the first attempts at 
generating these models can be traced back to several decades ago (Brinster et al., 1984; 
Greene and Arnold, 1945; Seligman et al., 1939). During the past years, a vast number of 
new models have been established utilizing the same strategies. These models essentially 
provided us with important insights in glioma biology and to some extent yielded information 
on therapeutic principles. The models have been used to identify the genetic alterations 
contributing to glioma initiation and progression, and to validate molecular mechanisms 
underlying the glioma proliferation and invasion, as well as to evaluate therapeutic targets in 
preclinical investigations.  
However, each model has its own limitations of recapitulating the disease. GBMs are thought 
to start from abnormal genetic events followed by dysregulation of signaling pathways in a 
small cell population, which contribute to glioma initiation and malignant transformation. 
During the tumor progression, glioma can possess histological inter- and intra-tumor 
heterogeneity. Simultaneously, the gliomas undergo interactions with the surrounding stromal 
cells, immune cells in particular, and modulations of the microenvironment, leading to 
gliomas expand and infiltrate into the brain parenchyma. At present there is no model that 
fully recapitulates the human GBM characteristics. Nevertheless, good utilization of models 
allows studying glioma biology in appropriate settings.              
Chemically induced syngeneic models 
Spontaneous gliomas are seldom reported in rodents. In early studies, the glioma models 
were induced in animals by treating them with DNA alkylating agents such as N-
nitrosomethylurea (Schmidek et al., 1971). The alkylation of DNA bases results in base 
mispairing, generation of a damaged DNA template and further gene point mutations. These 
models have been primarily generated in rats including 9L, C6 and CNS-1, also some in mice 
like GL261 (Stylli et al., 2015). However, chemically induced gliomagenesis may vary to a 
large degree in the occurrence, incidence and malignancies.  
The rodent glioma cell lines derived from these models have been widely used for in vitro 
studies and for constructing syngeneic models with high reproducibility. The cell lines 
normally are transplanted to a syngeneic immunocompetent host by an orthotopic approach. 
It is therefore a great advantage of these models that allows the developing tumor to interact 
with the intact immune system. These models are particularly valuable for the experimental 
studies on the mechanisms behind immune responses during glioma progression and 
invasion. For instance, one study using GL261 model reported the inhibition of transforming 
growth factor-β (TGF-β) reverses glioma induced immunosuppression (Ueda et al., 2009). 
Also the GL261 model has been widely adopted for testing of experimental immunotherapy 
in preclinical studies (Maes and Van Gool, 2011). It is worth noting that the vigorous 
induction of systematic immune reaction can lead to tumor rejections in the model. In one 
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study, all the rats survived after receiving C6 glioma cells both in the flank and brain, in 
contrast to 11% survival rate in those only implanting C6 cells in the brain (Parsa et al., 
2000). 
Human cell based xenograft models 
The xenograft models are the most common models used for preclinical studies on glioma 
growth and progression. The establishment of such models involves the intracranial 
transplantation of human glioma cell lines or patient biopsy spheroid into the 
immunodeficient mice. Biopsy samples from GBM patients are subjected to tissue culture in 
medium containing serum for several passages to establish human monolayer cell lines. The 
vast quantities of glioma cells yielded by culture of human cell lines are sufficient for 
experimental use, especially for studies involving a large cohort of mice. Moreover, the 
human cell lines are genetically more relevant to human gliomas than the chemically induced 
cells. Yet, human cell lines have been adapted to the in vitro culture selection and the cell 
population became more homogeneous in culture. Besides, studies reported the genomic 
landscapes of glioma cell lines differ from that of original GBMs (Allen et al., 2016; Li et al., 
2008).  
Modification has been made to culture the biopsy material as neurospheres in neurobasal 
medium with no serum. The cells isolated from the sphere culture displayed cancer stem cell 
characteristics (Galli et al., 2004). The xenograft model inoculated with caner stem cells 
highly recapitulated the profiles of primary GBM (Lee et al., 2006). However, it is reported 
the success rate of performing neurosphere assay on primary gliomas varies to a large extent 
(Wan et al., 2010). Instead of a long term culture, the biopsy material from GBM patients can 
be minced with blade and then subjected to tissue culture in a short time allowing for the 
formation of spheroids. In addition, tumors that are difficult to grow in vitro can be passaged 
in nude mice. Such biopsy spheroids preserved many original tumor features as well as the 
genomic signatures of human GBM (De Witt Hamer et al., 2008). The biopsy spheroid 
xenograft model is clinically relevant since it well resembles the original tumor. At the same 
time, these models are variable due to the intra- and inter-tumor heterogeneity nature of 
GBMs. 
Genetically engineered mouse models  
The genetically engineered mouse (GEM) is a valuable tool to study genetic alterations that 
contribute to glioma initiation and progression. In this model, the entire immune system is 
maintained, allowing it to faithfully reflect tumor immunology and microenvironment. The 
GEM model bears the tumor formed in situ which retains the etiological and pathological 
events as well as the histological traits of gliomas. GEM models are produced by genomic 
manipulations in a transgenic or gene knock-out manner to study gene functions. Several 
GEM models have been created on the thought of modulating the central signaling pathways 
perturbed in human gliomas. These include pathways such as PDGF, EGFR, TP53, Rb, 
PTEN, Ras and Akt (Holland et al., 2000; Huszthy et al., 2012; Uhrbom et al., 1998). 
However, GEMs possess the altered genes of interest in all the cell types, which may cause 
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embryonic lethality in some models (Schmid et al., 2012). The glial fibrillary acidic protein 
(GFAP) is almost exclusively expressed in astrocytes. Therefore, GFAP is widely used as the 
ideal promoter in transgenic mice to restrict genes modifications in astrocytes (Danks et al., 
1995). Similarly, the S100b promoter has been used to generate the mice expressing v-erbB 
which is a homologous oncogene to EGFR. The overexpression of S100b-v-erbB initiated 
low grade glioma in mice followed by its transition to high grade mediated by mutations in 
p53 pathway (Weiss et al., 2003).  
Gene manipulations can be performed not only on germline, but also on somatic cells. The 
somatic gene transfer enables the gene alterations occurring in a small number of cells, which 
mimic the natural process of tumor initiation. The frequently used methodology is to deliver 
selected oncogenes to the target cells by RCAS/tv-a system (Dai et al., 2001; Holland et al., 
1998; Uhrbom et al., 2002). The general idea is that the avian retrovirus RCAS can be 
constructed to encode exogenous oncogenes, while its receptor tv-a can be engineered into 
transgenic mice under any cell specific promoter (e.g. GFAP in Gtv-a mice). Subsequently, 
upon injection of the transfected cells producing RCAS viral particles, the tumor is initiated 
but restricted by cell type and location. However, it should be taken into account the GEM 
models may have long tumor-free latency periods and low penetrance rates. 
1.2.4 THE IMMUNE MICROENVIRONMENT OF GLIOMA  
The heterogeneity of glioma is not only attributed to the transformed malignant cells per se 
but also to various stromal cells. The glioma stroma includes cellular components such as 
numerous immune cells, astrocytes, neurons, endothelial cells and fibroblasts. In addition, 
there are non-cellular elements surrounding the glioma including cytokines, chemokines and 
brain extracellular matrix (ECM). Moreover, during glioma progression, the normal brain 
vasculatures are disrupted as evidenced by breakdown of the BBB and induction of tumor 
angiogenesis (Davies, 2002; Jain et al., 2007). Massive traffic of a range of immune cells 
takes place from the periphery to the brain once the BBB is compromised in diseases (Weiss 
et al., 2009). All these factors together create a unique microenvironment of glioma, which 
plays vital roles in glioma growth, invasion and resistances to treatments. Nevertheless, the 
glioma microenvironment is subjected to dynamic changes during glioma progression. In the 
initial and early stage of glioma, the brain vasculature remains intact and thus there is no 
recruitment of peripheral immune cells. 
Numerous immune cells are present in glioma which primarily consist of microglia, myeloid-
derived suppressor cells (MDSCs), dendritic cells (DCs), tumor-associated macrophages 
(TAMs) and lymphoid cells (Figure 2). The tumor-infiltrating cells of myeloid linage, 
microglia, TAMs and MDSCs, are thought to be converted to a tumor-supportive phenotype 
shaping the tumor immunosuppressive niche (Gabrilovich et al., 2012; Wu et al., 2010). 
Among all the infiltrating cells, microglia and TAMs together have been identified as the 
predominant population in brain tumors (Morantz et al., 1979). A recent study demonstrated     
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that microglia (CD11b
+
CD45
low
CD33
–
), MDSCs (CD11b
+
CD45
med
CD33
+
) and TAMs 
(CD11b
+
CD45
high
CD33
–
) represent approximately 40%, 40% and 20% of the myeloid 
population in human GBM tumor mass, respectively (Gabrusiewicz et al., 2016). 
 
Figure 2. Illustration of the immune microenvironment of glioma.  
Adapted from a figure from an open access article (Mostofa et al., 2017).  
Under pathological conditions, bone marrow-derived monocytes traffic to the blood 
circulation and further migrate to the diseased tissues, giving rise to macrophages or dendritic 
cells (Shi and Pamer, 2011). As consequence of the disruption of the BBB, the circulating 
monocytes are recruited towards the brain and further differentiate into peripheral 
macrophages. In respect to gliomas, TAMs act in a similar way as microglia in promoting 
tumor progression. Yet, the functions of TAMs that distinguish them from microglia in tumor 
biology remains to be uncover. It has been difficult to segregate TAMs from microglia under 
pathological conditions due to the absence of highly specific markers. The expression level of 
CD45 is commonly used in flow cytometry to separate TAMs (CD45
high
) and microglia 
(CD45
low
) from mice model. A few promising markers distinguishing microglia from TAMs 
have been identified in recent years, which includes Tmem119, Siglec-H, Olfml3 and Cx3cr1 
(Bennett et al., 2016; Chiu et al., 2013; Gautier et al., 2012).  
MDSCs are a heterogeneous myeloid progenitor and immature myeloid cell population 
deriving from bone marrow. Under physiological conditions, immature myeloid cells 
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differentiate into neutrophils, macrophages and DCs. But in pathological conditions like 
cancer, the regulated myeloipoiesis is perturbed, leading to the expansion of MDSCs which 
later migrate to the tumor site and promote tumor growth (Marvel and Gabrilovich, 2015). 
Indeed, MDSC accumulation was found in peripheral blood in GBM patients (Raychaudhuri 
et al., 2011). Moreover, MDSCs were not detected in normal brain parenchyma but in 
resected human GBM tissue (Gabrusiewicz et al., 2016). In mice models, MDSCs (Gr-1
+
) 
population increase significantly 21 days post transplantation of GL261 cells in the brain, as 
accounting for about 3% brain cells and 20% blood cells (Alizadeh et al., 2010). MDSCs 
have immunosuppressive functions in tumor microenvironment, which is to inhibit natural 
killer (NK) cells activities and to suppress the responses of helper CD4
+
 T cells and cytotoxic 
CD8
+
 T cells (Marvel and Gabrilovich, 2015). The T cell responses are dampened through a 
mechanism dependent on nitric oxide (NO) released from MDSCs (Raber et al., 2014).  
In the immune system, DCs function as the professional antigen presenting cells (APCs). 
DCs derive from bone marrow and have crucial functions in linking innate and adaptive 
immunity. They have the capacity to capture antigens, process them into peptides, present 
peptides on its cell surface to T cells, and eventually stimulate the adaptive immune response. 
The studies on DCs in gliomas have been mainly focused on DC based vaccines. In one early 
clinical trial, DCs were cocultured with autologous glioma lysate overnight, and then they 
were verified and injected into patients followed by administration of Toll-like receptor 
(TLR) agonists. The median overall survival of GBM patients receiving the DC vaccine was 
prolonged compared to historical controls, particularly of those bearing GBM mesenchymal 
subtype (Prins et al., 2011).  
Despite the predominant infiltration of myeloid-derived cells, lymphoid cells also infiltrate 
gliomas. NK cells are innate cytotoxic lymphocytes capable of eliminating microbe-infected 
cells and tumor cells (Vivier et al., 2008). NK cells are not involved in low grade gliomas, 
but they represent a minor population (approximately 2%) of all infiltrating immune cells in 
GBM biopsies (Kmiecik et al., 2013). One ex vivo study demonstrated activated NK cells can 
kill GBM stem-like cells that are isolated from patients (Castriconi et al., 2009). However, 
NK cells activities are impaired in gliomas likely due to the suppression mediated by MDSCs 
and T regulatory cells (Ogbomo et al., 2011). The number of both tumor infiltrating CD4
+ 
helper and CD8
+
 cytotoxic T cells increase according to the grade of gliomas, while the 
FoxP3
+
 T regulatory cells are present commonly in GBM specimens but rarely in low grade 
gliomas (Heimberger et al., 2008). Both of the helper and cytotoxic T cells from GBM 
biopsies were manifested with a suppressed phenotype, while the CD8
+
CD28
−
Foxp3
+
 T 
regulatory cells are present in GBM biopsies but absent in the control counterparts (Kmiecik 
et al., 2013). However, the CD4
+
 and CD8
+
 T cells are not properly activated due to 
suppression by cytokines, such as TGF-β and IL-10, secreted in the niche and inhibition by 
other cells. In fact, malignant gliomas induce microglia and TAMs to produce cytokines as 
well as to recruit MDSCs and T regulatory cells to the tumor microenvironment (Perng and 
Lim, 2015). 
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1.3 CASPASES 
Caspases (cysteine dependent aspartate directed proteases) are a group of proteases highly 
conserved among organisms. Caspases act as critical regulators of programmed cell death and 
inflammation. The catalytic active sites in caspases are cysteine residues which cleave the 
substrates by cutting peptide bonds specifically at certain aspartic acid residues. Caspases are 
recognized for their essential role in triggering cell apoptosis, resulting in DNA 
fragmentation, cell shrinkage and plasma membrane blebbing (Elmore, 2007). In recent 
years, several non-apoptotic roles of caspases have emerged with regard to regulate cellular 
functions. 
1.3.1 CLASSIFICATION OF CASPASES 
Based on function, human caspases can be divided into apoptotic and inflammatory caspases. 
Caspase-2, -3, -6, -7, -8, -9 and -10 are well known for their apoptosis related functions, while 
caspase-1, -4, -5 and -12 have inflammatory roles. According to the precise role in apoptosis, 
the apoptotic caspases can be divided into two subgroups: initiator caspases including 
caspase-2, -8, -9 and -10; effector/executioner caspases including caspase-3, -6 and -7. The 
upstream initiator caspases recognize and hydrolyze a few protein substrates including 
inactive effector caspases, whereas the downstream effector caspases cleave a much broader 
range of substrates.  
1.3.2 ACTIVATION OF CASPASE-3 AND THE REGULATION 
Caspases are produced in cells as inactive zymogens (monomer pro-caspases) that need to 
undergo dimerization and cleavage to become active. The activation of effector caspases 
depend on cleavage by initiator caspases. Initiator caspases are activated when dimerization 
occurs followed by stabilization through autocatalytic cleavage, which are dependent on the 
initiation by an intrinsic or extrinsic signaling pathway in the context of cell death (Boatright 
and Salvesen, 2003; Chang et al., 2003). The intrinsic pathway is activated when either 
severe cell injury (e.g. DNA damage, viral infection) or absence of trophic factor occurs, in 
which the mitochondrial membrane barrier is disrupted, followed by cytochrome c releasing 
into cytosol. Afterwards, pro-caspase-9, cytochrome c and apoptotic protease-activating 
factor-1 (Apaf-1) are recruited to build the multi-protein apoptosome complex (Shiozaki et 
al., 2002). The activation of caspase-9 in apoptosome leads to subsequent caspase-3 
activation which triggers apoptosis. Alternatively, the extrinsic pathway is activated upon 
stimulation of death receptors like TNF and Fas, which results first in caspase-8 activation 
and latter caspase-3 activation. 
Activation of caspase-3 has been linked with apoptosis for long time. However, one novel 
study altered our understanding of roles of caspase-3 plays in cell biology (Burguillos et al., 
2011). In this study, it was shown that stimulation of Toll-like receptor 4 (TLR-4) by 
lipopolysaccharide (LPS) leads to sequential activation of caspase-8 and caspase-3 but with 
absence of cell death. Caspase-3 cleaves protein kinase C-δ (PKC-δ) enabling it to become 
active, which in turn activates the IκB kinase (IKK) complex. Thereafter IKK phosphorylates 
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IκB protein, the inhibitor of transcription factor NF-κB, leading to its degradation. Once 
released from the inhibitor, NF-κB undergoes translocation into the nucleus which promote 
the expression of a range of pro-inflammatory factors such as NOS2, TNF-α and IL-1β. Thus, 
moderate induction of caspase-3 activity regulates microglia activation towards a pro-
inflammatory phenotype and associated neurotoxicity (Figure 3) (Venero et al., 2011).  
 
Figure 3. Caspases controls microglial pro-inflammatory polarization. 
Adapted from (Venero et al., 2011). Reprinted with permission from Nature Publishing Group. 
Moreover, it have been uncovered the mechanisms that restrict caspase-3 from committing 
cell death during microglia activation. As described above, pro-caspase-3 requires the 
cleavage by initiator caspases, caspase-8 in this context, for activation. However, this 
processing conducted by caspase-8 only generates active caspase-3 in the intermediate form 
p19/p12 complex which stays in the cytoplasm. Upon occurrence of further autocatalytic 
cleavage, caspase-3 (p19/p12) becomes fully active in the form p17/p12 leading to its 
relocation to nucleus to perfom its apoptotic function. The cellular inhibitor of apoptosis 
proteins (cIAPs) are a family of natural inhibitors for caspases that play a major role in 
regulating caspases activation (LeBlanc, 2003). During the pro-inflammatory microglia 
activation, the expression cIAP2 is upregulated which prevent the processing of caspase-3 
subunit p19 to p17, thereby controling caspase-3 activity and translocation (Kavanagh et al., 
2014). 
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1.3.3 NON-APOPTOTIC ROLE OF CASPASES 
Caspases have multiple physiological functions besides executing cell death. These include 
regulatory functions in immunity, cell proliferation, differentiation and migration. Caspase-1 
is a cysteine protease recognized for its role in converting pro-IL-1β to IL-1β (Thornberry et 
al., 1992). In response to infectious events, caspase-1 activation occurs through the 
inflammasome in macrophage that induce production of inflammatory factors IL-1β, IL-18 
and IL-33 (Arend et al., 2008; Nadiri et al., 2006). Patients inherited homozygous caspase-8 
deficiency manifest defects in activation of all types of lymphocytes resulting in 
immunodeficiency (Chun et al., 2002). Knockout of caspase-8 causes embryonic death in 
mice, implying it is vital during embryonic development (Varfolomeev et al., 1998). Mice 
with caspase-8 knockout specifically in T lymphocyte display defective T cell proliferation 
and impaired response to stimulation (Salmena et al., 2003). In contrast, mice with 
homozygous caspase-3 knockout have enhanced proliferation of B cells (Woo et al., 2003).  
It has been shown that caspases facilitate cell terminal differentiation by removing nucleus in 
keratinocytes, lens cell, megakaryocytes and erythroid cells (Lamkanfi et al., 2007). 
Activations of caspases are required for human monocytes to differentiate into macrophage 
upon stimulation by M-CSF (Sordet et al., 2002). Moreover, caspase-3 deficient mice were 
found displaying defects in differentiation of skeletal muscle and osteoblasts (Fernando et al., 
2002; Miura et al., 2004). It has been reported that mouse embryonic fibroblasts (MEFs) 
lacking caspase-8 exhibit deficiency in calpain proteolytic pathways which are responsible 
for cell motility (Helfer et al., 2006). Caspase-8 expression level is frequently upregulated in 
tumor cells. One explanation is that caspase-8 can promote calpain activation independent of 
its catalytic activity, which in turn enhances tumor cell migration (Barbero et al., 2009). 
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1.4 NITRIC OXIDE 
Nitric oxide (NO) is a colorless gas with short half-life, and it is free radical harboring one 
unpaired electron (Hakim et al., 1996). NO is soluble both in water and in organic solvents 
which allow it to pass easily between cells. NO is a potent molecule reacting rapidly with 
other components. It severs as an signaling molecule which play a physiological role of 
importance particularly in nervous system (neurotransmitter), cardiovascular system (control 
of blood pressure) and immune system (killing of microbes) (Hirst and Robson, 2011). 
However, excessive NO has detrimental effects on cells that can cause cell damage and 
apoptosis. Moreover, the controversial functions of NO during the course of tumor 
progression have been emerging in recent years (Choudhari et al., 2013). The mechanism of 
intracellular NO signaling is mediated by cyclic guanosine monophosphate (cGMP) or based 
on redox modifications of cysteines (S-nitrosylation and denitrosylation) (Murad, 1994; 
Stamler et al., 2001).  
1.4.1 BIOLOGICAL SYNTHESIS OF NITRIC OXIDE 
In mammalian cells, nitric oxide synthase (NOS) produce NO by converting L-arginine to L-
citrulline, which is dependent on NADPH and oxygen. Mammalian cells harbor genes 
encoding three isoforms of NOS: NOS1/nNOS, NOS2/iNOS and NOS3/eNOS. NOS1 and 
NOS3 are constitutively expressed in neurons and endothelial cells, respectively. NOS1 and 
NOS3 activities are dependent on Ca
2+
 and regulated by posttranslational phosphorylation 
(Lee et al., 2005). On the other hand, cellular NOS2 expression is induced by a wide 
spectrum of inflammatory stimuli such as LPS, TNF-α and IL-1β, whereas NOS2 induction is 
inhibited by factors like TGF-β, IL-4 and IL-10. The NOS2 activity is Ca2+-independent but 
is subjected to regulation at the transcriptional level. Therefore, the induction of NOS2 
usually leads to production of NO in large quantities over an extended period of time until the 
NOS2 expression is under control (Kleinert et al., 2003). NOS2 is vital in mediating immune 
responses against infectious microbes and cancer, but it also has pathological effects when 
massive production of NO occurs.  
1.4.2 NITRIC OXIDE IN TUMOR BIOLOGY 
Elevated activity of NOS and increased level of NO have been detected in various types of 
cancer (Choudhari et al., 2013). For instance, one early study demonstrated high levels of 
NOS expression and NADPH staining in astrocytic gliomas, along with the observation that 
the highest NOS activity is found in higher grade gliomas (Cobbs et al., 1995). Likewise, 
glioma patients manifest enhanced expression of NOS1 in tumor cells and increased NOS1 
according to the grade of tumor, also raised NOS3 expression in vascular endothelial cells 
(Broholm et al., 2003). These findings indicate NO production is involved in tumor biology 
and shape of tumor microenvironment. Furthermore, it has been proposed NO can modulate 
several critical events in tumor progression such as angiogenesis, invasion and metastasis 
(Ying and Hofseth, 2007). However, the precise effect of NO in cancer has been under debate 
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with current notion that NO plays dual roles in tumor biology. It seems NO can both promote 
and prevent tumor cell growth and proliferation.  
Special attention should be given to NOS2, since its expression is the most variable among all 
NOS isoforms. Upon stimulation, macrophage NOS2 are capable of killing tumor cells by 
producing large amount of NO (60µM) (Xu et al., 1998). Mice lacking NOS2 developed 
substantially more intestinal adenomas than their control counterparts, indicating NOS2 may 
have an anti-tumorigenesis function (Scott et al., 2001). In contrast, NOS2 has been revealed 
as a mediator of angiogenesis as NOS2 expression is positively associated with angiogenic 
activity in various types of tumors (Fukumura et al., 2006). The possible mechanisms 
underlying NO anti- and support-tumor roles require further investigations. NO effect is 
largely dependent on concentrations as high dose of NO causes apoptosis but lower 
concentration (nanomolar) of it promotes tumor cell proliferation (Pervin et al., 2007). There 
are several other variable factors involved in NO functions in tumor including the timing, 
duration and location of exposure, stage of the developing tumor as well as the overall redox 
state of tumor cells. 
1.4.3 PROTEIN S-NITROSYLATION AND DENITROSYLATION  
NO signal transduction regulates cellular functions partly by conducting posttranslational 
modifications on proteins. The covalent addition of NO to cysteine thiol (Cys-SH) is termed 
protein S-nitrosylation. The resultant protein harboring a cysteine nitrosothiol (Cys-SNO) is 
named S-nitrosylated protein (SNO-protein). Protein denitrosylation refers to the reverse 
process of S-nitrosylation, which is the conversion of Cys-SNO to Cys-SH. The reactions 
rates of nitrosylation and denitrosylation determine the level of S-nitrosylation occurs on any 
given protein (Figure 4). 
 
Figure 4.  Mechanisms of protein S-nitrosylation and denitrosylation. 
Adapted from (Benhar et al., 2009). Reprinted with permission from Nature Publishing Group. 
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Like phosphorylation and ubiquitylation, S-nitrosylation is a common modification that 
occurs on numerous proteins. A wide range of SNO-proteins are constitutively expressed at a 
low level in intact cells such as pro-caspase-3, GTPases and the ryanodine receptor (Hess et 
al., 2005). S-nitrosylation essentially modifies protein activity, stability, interactions and its 
subcellular localization (Benhar et al., 2009). The NO group attached to protein in S-
nitrosylation is produced by endogenous NOS or from exogenous higher nitrogen oxides (e.g. 
NO2
-
 NO3
-
). It has been shown that endogenous protein nitrosylation is dependent on direct 
binding of NOS to proteins or subcellular localization of NOS (Iwakiri et al., 2006; Kim et 
al., 2005). Moreover, protein S-nitrosylation can occur in a manner of transnitrosylation 
between proteins. One transnitrosylation reaction involves a nitroso (NO
+
) transfer between 
an SNO and an acceptor thiol.  
On the other hand, protein denitrosylation is primarily mediated by S-nitrosoglutathione 
reductase (GSNOR) and thioredoxin (Trx) systems. Glutathione (GSH) can denitrosylate 
SNO-protein by converting SNO to a reduced thiol, coupling with the formation of GSNO 
which are subsequently metabolized by GSNO in a NADH dependent fashion. However, 
GSNOR only denitrosylate GSNO but no other SNO-proteins, thus it acts indirectly in 
protein denitrosylation (Liu et al., 2001). In contrast, the Trx system has been identified as 
the direct regulator on protein denitrosylation (Benhar et al., 2008). 
1.4.4 THE THIOREDOXIN SYSTEM 
The Trx system comprise of Trx, Trx reductase (TrxR) and NADPH. Trx is a 12 kD redox 
protein and is present in all organisms conserved from bacteria to human (Lillig and 
Holmgren, 2007). Mammalian species possess two universally expressed Trxs, cytosolic 
Trx1 and mitochondrial Trx2, and the testis specific Trx3 (Jimenez et al., 2004). Trx proteins 
have an active site Cys-Gly-Pro-Cys (CGPC) that is responsible for transferring electrons 
from NADPH to protein substrates, with involvement of TrxR. Thereby, Trx systems 
function as disulfide reductases for several cellular proteins (Lillig and Holmgren, 2007). For 
instance, Trx was originally characterized by its capacity of providing electron to 
ribonucleotide reductase (RNR) which is an enzyme central in synthesizing DNA (Holmgren, 
1985).  
Several studies have found that the Trx system also plays a major role in protein enzymatic 
denitrosylation (Benhar et al., 2008; Sengupta et al., 2007; Stoyanovsky et al., 2005). It has 
been reported that the Trx system can restore NO-induced reduction of cellular protein 
activity (Kahlos et al., 2003; Zhang et al., 1998). One landmark study illustrated that Trx 
systems are capable of regulating both the constitutive basal and the stimulus-induced 
denitrosylation of caspase-3 (Benhar et al., 2008). Trx can mediate protein denitrosylation 
through two likely biochemical mechanisms which generate intermediate product Protein-S-
S-Trx or Trx-SNO.  
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However, some other studies proposed the concept that human Trx1 can promote protein 
nitrosylation through the non-active site Cys
69
 or Cys
73
 (Haendeler et al., 2002; Mitchell et 
al., 2007). This idea indicates Trx1 may be involved in protein transnitrosylation, but not 
Trx2 since it lacks these Cys residues. Similar to protein nitrosylation, denitrosylation can 
also occur in cellular compartments. For example, in lymphocytes most SNO-caspases are 
localized in mitochondria. Upon induction of apoptosis, SNO-caspase-3 undergoes 
denitrosylation by the upregulated Trx2 in mitochondria, therefore facilitating subsequent 
caspase-3 activation (Benhar et al., 2008; Mannick et al., 2001).  
It has been raised the notion that activity of Trx systems are subjected to regulatory 
mechanisms according to cellular nitrosative stress such as the level of NO and SNO-proteins 
(Benhar et al., 2009). Moreover, it was revealed Trx mediated denitrosylation is regulated by 
its endogenous inhibitor thioredoxin-interacting protein (Txnip), and Txnip itself is repressed 
by NO that allowing Trx system cope with nitrosative stress (Forrester et al., 2009). Txnip is 
localized in the cytosol and in the nucleus where Txnip binds reduced Trx (Trx-(SH)2) and 
oxidize it, while Txnip does not interact with oxidized Trx (Trx-(S)2) (Patwari et al., 2006). 
Interestingly, in response to H2O2 treatment or Txnip overexpression, Txnip can translocate 
from the nucleus to mitochondria and convert Trx2-(SH)2 to Trx2-(S)2 (Saxena et al., 2010). 
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1.5 NEURAL STEM CELLS 
Neural stem cells (NSCs) are multipotent cells capable of self-renewing and generating 
neurons, astrocytes and oligodendrocytes throughout life. In the postnatal brain, NSCs reside 
in two discrete neurogenic niches, the subventricular zone (SVZ) and the subgranular zone 
(SGZ), where they function as a source of neurons and glia cells in adult mammalian brain 
(Lois and Alvarez-Buylla, 1994; Luskin, 1993). Adult NSCs remain in quiescent state and 
they transit to active state upon stimulation by extracellular signals such as endothelial cell-
derived growth factor (Sun et al., 2010). Once activated, NSCs undergo either asymmetric 
division generating a progenitor and a NSC, or symmetric division giving rise to two 
progenitors (non-self-renewal). Progenitors subsequently differentiate into neuronal or glial 
cell types (Bond et al., 2015). Adult radial glia-like NSCs in SVZ (type B cells) divide and 
yield transient amplifying progenitors (type C cells) followed by production of neuroblasts 
(type A cells) after a few divisions (Doetsch et al., 1999). The neuroblasts migrate to the 
olfactory bulb in the form of chains and differentiate into mature interneurons. In the SGZ 
niche, NSCs (type 1 cells) generate intermediate progenitor cells which amplify themselves 
and give rise to neuroblasts, eventually maturing into dentate granule cells in hippocampus 
(Berg et al., 2015; Seri et al., 2001). Since the concept of adult neurogenesis was established, 
NSCs have been considered as an endogenous tool to replace damaged neurons and repair the 
diseased brain (Bellenchi et al., 2013). 
GBM contains a glioma stem cell (GSC) population that share several traits with stem cells 
and manifest capacity of self-renewing, maintaining proliferation and differentiating to 
multiple cell lineages (Galli et al., 2004; Singh et al., 2003; Stiles and Rowitch, 2008). These 
GSCs are thought to confer resistance to radiotherapy and chemotherapy (Bao et al., 2006; 
Eramo et al., 2006). The origin of GSCs remains elusive as they are proposed to be 
transformed from differentiated astrocytes, neural progenitor cells, or directly NSCs 
(Mangum and Nakano, 2012). In particular, SVZ NSCs has been thought of as the source that 
may give rise to some human gliomas (Lim et al., 2007; Sanai et al., 2005). One study 
utilizing transcriptome analysis revealed that human biopsy-derived GSCs and adult NSCs 
share common markers related to stem cells and lineages, but GSCs display a more 
heterogeneous gene expression profile than adult NSCs. Moreover, GSCs represent a 
spectrum of GBM molecular subtypes, while adult NSCs homogeneously correlate with the 
neural subtype (Sandberg et al., 2013). 
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2 AIMS OF THE THESIS 
 
Microglia are innate immune cells that reside in the CNS throughout life. They interact with 
other cellular elements in both healthy and diseased brain. The general aim of my studies was 
to investigate the functional roles of microglial cells in glioma biology and neural stem cell 
biology, as well as to study the molecular mechanisms behind the communications between 
microglia and glioma cells. 
The specific aims of the present studies were: 
Paper I To investigate caspase signaling pathways in glioma associated-microglia activation 
and to decipher the mechanisms underlying the polarization of microglia towards tumor-
supportive phenotype controlled by glioma cells 
Paper II To explore microglia that exhibit pro-inflammatory or anti-inflammatory phenotype 
impacts on neural stem cell function 
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3 RESULTS AND DISCUSSION 
 
Paper I Glioma-induced inhibition of caspase-3 in microglia promotes a tumor-
supportive phenotype 
In this study, we firstly measured and quantified caspases activity in both in vitro and in vivo 
models. For the in vitro approach, we established a segregated cell coculture setting that was 
used for most of the coculture experiments throughout the study (Supplementary Fig. 1a). In 
the upper compartment we seeded microglia cells, while on the bottom of the dish we 
cultured a monolayer of glioma cell lines of various origins. Thereby, the microglia and 
glioma cells communicate with each other through soluble factors in the medium.  
We detected a significant reduction in BV2 microglial DEVDase activity, which reflects 
caspase-3 like activity, upon segregated coculture with different glioblastoma cell lines for 6h 
and 24h (Fig. 1a). At the same time BV2 microglial LETDase activity, which accounts for 
caspase-8 activity, was marginally changed upon coculture with glioma cells for 6h and 24h 
(Supplementary Fig. 1b). Next, we found a similar decrease of caspase-3 like activity in 
microglia that were subjected to the joined coculture setting in which glioma cells physically 
contact with microglia (Fig. 1b). Furthermore, we confirmed the effect in human microglia 
and primary microglia segregated cocultured with glioma cells of distinct origins, as well as 
in BV2 microglia and primary murine microglia cultured with glioma-conditioned medium 
(Fig. 1c-e).  
These observations indicate that glioma cells decrease caspase-3 like activity in microglia 
independent of microglial caspase-8, which is carried out effectively through glioma-derived 
soluble factors. It is worth to note that the pro-inflammatory polarization of microglia 
depends on the orderly activation of caspase-8 and caspase-3 upon stimulation of TLR-4 
(Burguillos et al., 2011). This implies that the glioma-associated microglial activation 
involves a caspase-3 signaling pathway which differs from that in pro-inflammatory 
microglia activation.  
The reduction in microglial basal caspase-3 like activity correlates with a decrease of the 
cleaved form of caspase-3 (p19) and an increase of the procaspase-3 upon coculture for 6h 
(Fig. 1f-g). Currently it is known procaspase-3 is processed to p19 subunit, which is not fully 
active yet and requires to be further cleaved to become p17 to conduct apoptotic functions 
(Han et al., 1997; Kavanagh et al., 2014). Collectively, these data indicate that the cleavage 
of basal procaspase-3 and the corresponding caspase-3 activity were inhibited in microglia by 
glioma cells.  
To validate the in vitro results, we established an in vivo mouse GL261 glioma model 
(Supplementary Fig. 1c). The GL261 glioma model is widely used for glioma experimental 
investigations, in particular adopted for studying immune cells functions in glioma biology 
since the model recapitulate the immune microenvironment. In addition, this mice model has 
been shown to exhibit limited infiltration by peripheral monocytes/macrophages, at the time 
points we used in our study (Muller et al., 2015). We quantified the levels of microglial 
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cleaved caspase-3 in the regions inside the tumor and at the border of tumor, at different time 
points post tumor transplantation. We found that the florescence intensity of microglial 
cleaved caspase-3 within the tumor is much lower as compared to the microglia present in the 
border at one and two weeks after tumor transplantation (Fig. 1h-j). 
To investigate the functional outcome of the decrease in basal caspase-3 like activity in 
microglia, gene expression profiling and functional assays were carried out in microglia 
subjected to caspase-3 knockdown. BV2 cells were transfected with siRNA against caspase-3 
or scrambled control (Fig. 2a), and caspase-3 like activity indeed decreased in microglia 
transfected with siRNA caspase-3 (Fig. 2b), which enabled us to mimic the glioma effect on 
microglia caspases. Transfected microglia cells were included in the coculture experiments 
and later they were checked for the expression of genes that are central to wound-healing 
process. These gene products are involved in cell proliferation, tissue remodeling and 
immunosuppression, thus possessing pro-tumorigenic properties (Dvorak, 1986). The 
profiling analysis revealed that several genes were upregulated in microglial treatment groups 
compared with their control counterparts, which indicates both knockdown of caspase-3 in 
microglia and glioma effects on microglia can induce a microglial tumor-supporting 
phenotype. In addition, the silencing of microglial caspase-3 worked in synergy with glioma 
effects on microglia (Fig. 2c).  
Of note, the most upregulated gene product was IL-6 in microglia. It has been showed that 
IL-6 functions in promoting glioma stem cell growth, maintaining microglial pro-tumoral 
functions, and correlated with poor survival of glioma patients (Wang et al., 2009; Zhang et 
al., 2012). Furthermore, we utilized quantitative PCR (qPCR) to validate mRNA expression 
levels of IL-6 along with assessment of CCL-22, Ym1, MMP14 and NOS2. We found all the 
tumor-supportive markers (IL-6, CCL-22, Ym1 and MMP14) were upregulated, whilst pro-
inflammatory marker (NOS2) was downregulated, in microglia subjected to caspase-3 
silencing or coculture with glioma cells or both conditions (Fig. 2d).  
Finally, we observed that glioma cells migrate and invade further in the presence of siRNA 
caspase-3 transfected BV2 microglia as compared to siRNA control transfected ones (Fig 
2.e), which strengthens the hypothesis that decrease in basal caspase-3 like activity is 
involved in the induction of microglial tumor-supportive phenotype. 
The investigations until this step were based on microglia in surveying state. However, this 
scenario is rather marginal since during the formation of the GBM there is a massive 
recruitment of activated microglia/macrophages towards the tumor which subsequently 
polarized into a tumor-supportive phenotype (Voisin et al., 2010; Zhai et al., 2011). Thus, the 
next step was to study the strength of glioma cells-mediated inhibition of caspase-3 in 
activated microglia and the importance of that in inducing microglia tumor-supportive 
phenotype.  
Previously our lab reported that LPS induces microglial caspase-3 like activity and that 
increase of the activity promotes microglial inflammatory response (Burguillos et al., 2011). 
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We treated BV2 cells with LPS for 24h to let them fully polarized as pro-inflammatory 
phenotype, followed by a 6h coculture with glioma cells. We found that after 6h coculture, 
glioma cells effectively repressed LPS-induced microglial caspase-3 like activity and the 
expression of caspase-3 p19 subunit, as well as the inflammatory response induced by LPS 
(Fig. 3a, c, d). But LPS-induced caspase-8 activity in microglia was not affected by glioma 
cells (Fig. 3b).  
Our next step was to decipher the mechanism that glioma cells employ to induce the 
inhibition of caspase-3 like activity in microglia. We found that this inhibitory effect on 
caspase-3 was independent of the initiator caspase-8 activity (Supplementary Fig. 1b), and 
not attributed by potential alterations of mRNA expression levels (Supplementary Fig. 4a, b). 
Thus, caspase-3 activity in microglia is likely inhibited through certain modifications at 
posttranslational level. In recent years, the role of nitric oxide (NO) has been demonstrated to 
be critical for the etiology of GBM (Badn and Siesjo, 2010; Eyler et al., 2011). NO plays 
several roles in cell biology, one of which is to regulate caspases activity through S-
nitrosylation (Li et al., 1997; Melino et al., 1997). In fact, procaspase-3 is regulated through 
S-nitrosylation at its catalytic site Cys
163
 in a reversible manner (Benhar et al., 2008; Mitchell 
and Marletta, 2005).  
We initially examined the likelihood of NO involvement in the glioma cell-microglia 
communication leading to the decrease of basal caspase-3 like activity in microglia. We 
found that both L-NAME, a pan-inhibitor of NOS, and CPTIO, a NO scavenger, abrogated 
effectively the decrease of caspase-3 like activity in BV2 cells and primary microglia 
coculture with C6 glioma cells (Fig. 4a). Furthermore, we utilized two different techniques 
including biotin-switch method and in situ proximity ligation assay, and found that the level 
of SNO-procaspase-3 was increased in microglia cells after exposure to glioma cells in 
coculture (Fig. 4b, c). Finally we sought to find the origin of NO that causes S-nitrosylation 
of caspase-3. NOS2-specific inhibitor (1400W) but not pan-inhibitor of NOS (L-NAME) 
totally prevented the glioma-induced reduction of microglial caspase-3 activity (Fig. 4a). This 
data suggests NOS2-derived NO essentially act as a mediator in glioma cell-microglia 
communication.  
However, it is unclear which cell produced NO as both of microglia and glioma cells could 
be the potential source. Our previous data showed almost complete inhibition of mRNA 
expression of microglial NOS2 upon coculture with C6 glioma cells (Fig. 2d). In contrast, the 
NOS2 mRNA level was increased significantly in glioma cells under coculture condition 
(Fig. 4d). Moreover, NOS2 siRNA transfected C6 glioma cells but not BV2 cells abrogated 
partially the glioma-induced repression of microglial caspase-3 like activity (Fig. 4e, f). Thus, 
we found that it is the NOS2 activity in glioma cells that triggers the inhibition of caspase-3 
like activity in microglia.  
The process of protein nitrosylation in cells is negatively regulated by a family of small 
proteins named thioredoxins (Trxs) including Trx1 and Trx2 (Benhar et al., 2008). To 
identify the precise roles of each Trx in microglia, we selectively knocked down Trx1 or Trx2 
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(Supplementary Fig. 5a). BV2 cells transfected with siRNA Trx1 but not Trx2 manifested 
higher caspase-3 like activity than the control counterpart (Fig. 5a). In addition, glioma 
induced caspase-3 repression in BV2 cells transfected with siTrx2 were not as strong as in 
those with siTrx1 (Fig. 5a). Furthermore, the poor contribution of Trx1 to glioma induced 
effect on microglial caspase-3 was confirmed with using Trx1 specific inhibitor, PX-12, 
under coculture condition (Supplementary Fig. 5b).  
In fact, we found that increased S-nitrosylation occurred on Trx2 itself and that associated 
decreased Trx2 activity in microglia after coculture (Supplementary Fig. 5c, d). Moreover, 
both the Trxs and TrxRs activity in microglia were found reduced upon coculture with glioma 
cells (Supplementary Fig. 5d, e), indicating the glioma effects on microglial caspase-3 is 
coupled with the repression of Trx systems in microglia. In particular, knockdown of Trx2 in 
microglia mirrored the glioma effects on microglia with regard to the level of SNO-
procaspase-3 (Fig. 5b), which underscores that the deregulation of microglial Trx2 is 
necessary for glioma cells to achieve the effects.  
It has been reported protein nitrosylation can occur in cytosol and cellular compartments 
(Iwakiri et al., 2006; Kim et al., 2005). Next, we aimed to determine the subcellular location 
in microglia that glioma-induced SNO-procaspase-3 occurs. We found procaspase-3 was 
located in both cytosol and mitochondria, while cleaved caspase-3 was present only in 
cytosol which represented for the majority of cellular caspase-3 activity (Fig. 5c, d). In 
addition, upon coculture with glioma cells, caspase-3 like activity and the expression level of 
caspase-3 p19 subunit were decreased in microglial cytosol (Fig. 5c, d), whereas SNO-
procaspase-3 was accumulated mainly in microglial mitochondria (Fig. 5e). Taken together, 
these data suggest glioma induce microglia pro-tumoral activation partly through repression 
of Trx2-regulated denitrosylation of SNO-procaspase-3 in microglia mitochondria.  
Collectively, the data demonstrate that decrease of microglial caspase-3 like activity is 
required for its polarization into a tumor-supportive phenotype after exposure to glioma cells, 
and that this process depends on impaired Trx2-mediated denitrosylation of caspase-3 in 
microglia which is likely due to nitrosative stress origin from glioma cells.  
Next, we sought to examine the proposed signaling pathway in vivo. We started with 
inhibition of glioma NOS2 in vivo which is the initial component in the upstream of the 
pathway. We utilized NOS2 shRNA to stably knockdown NOS2 in GL261 glioma cells (Fig. 
6a). Targeting NOS2 in GL261 indeed abrogated the glioma effects on microglial caspase-3 
like activity (Fig. 6b). We transplanted the GFP-GL261 cells expressing shRNA-control or 
shRNA-NOS2 into C57/BL6/J mice brain. Using confocal microscopy, we found the mice 
receiving shRNA-NOS2 glioma cells displayed a substantially reduced volume of tumor and 
much less recruitment of microglia cells compared to the control counterparts at time of 1-
week and 2-week after tumor transplantation (Fig. 6c-f). Thus, it was validated in vivo the 
glioma-derived NOS2 is essential to recruit microglial cells towards tumor mass.  
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Ultimately, we attempted to validate the downstream of the signaling pathway involved in 
glioma cell-microglia crosstalk. The chemokine receptor CX3CR1 is a highly specific marker 
for microglia, allowing us to generate the conditional mice model bearing gene alterations 
restricted in microglia (Chiu et al., 2013; Gautier et al., 2012). We generated 
Casp3
flox/flox
Cx3cr1
CreERT2
 mice as the microglial caspase-3 knockout model upon tamoxifen 
treatment, and the Casp3
flox/flox 
mice treated as control (Fig. 7a). Following the previous 
procedure, we implanted GFP-GL261 glioma cells in Casp3
flox/flox 
mice and 
Casp3
flox/flox
Cx3cr1
CreERT2 
mice. The analysis performed on the brain tissues revealed the 
mice, subjected to deletion of microglial caspase-3, had developed tumors with greater 
volume than the control counterparts at 1-week and 2-week after tumor transplantation (Fig. 
7b-e). Thus, it was confirmed that in vivo depletion of microglial caspase-3 induced a 
microglial tumor-supportive phenotype promoting glioma growth and invasion. 
In summary, we identified glioma NOS2-produced NO leads to inhibition of Trx2 function in 
denitrosylating SNO-procaspase-3 in microglial mitochondria, further causes a decrease in 
microglial basal caspase-3 activity, ultimately results in the activation of microglia tumor-
supportive phenotype (Supplementary Fig. 7a). This study shed light on the role that caspase-
3 plays in the process of microglia polarization in the context of tumor biology. Deciphering 
the mechanism that regulates microglia pro-tumoral activation can provide us with suitable 
therapeutic options to prevent GBM expansion.  
Together with previous finding in the lab (Burguillos et al., 2011), we found that caspase-3 
might work as a modulator that controls microglial activation states in response to various 
stimuli (Supplementary Fig. 7b). The surveying microglia exhibit basal caspase-3 like 
activity, while the dying microglia display significant elevated caspase-3 like activity. 
Moreover, moderate increased caspase-3 like activity and reduced caspase-3 like activity 
below basal level promotes microglia polarization towards pro-inflammatory and tumor-
supporting phenotypes, respectively (Figure 5). 
 
Figure 5. Caspase-3 like activity regulates microglia polarization. From (Shen et al., 2017). 
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Paper II The secretome of microglia regulate neural stem cell function 
Microglia are essential cellular elements that reside in the neurogenic niches, they regulate 
adult neurogenesis, and they communicate with neurons (Gemma and Bachstetter, 2013). In 
response to brain injury, microglia undergo polarization and recruitment towards the affected 
area where they mediate tissue repair (Mallat et al., 2005; Wynn et al., 2013). In this study, 
we investigated the differential influences of microglia that displays distinct properties on 
neural stem cells (NSCs) functions.  
We firstly stimulated BV2 microglial cells with LPS or IL-4 in order to induce microglial 
pro-inflammatory or anti-inflammatory phenotypes, respectively (Fig. 1c, d). Next, the 
validated multipotent NSCs (Fig. 1a, b) were exposed to conditioned medium collected from 
stimulated microglia, and subsequently NSCs were examined for gene expression profile and 
cellular functions in the aspect of survival, proliferation, migration, and differentiation.  
We found that NSCs cultured in pro-inflammatory microglia conditioned medium showed 
worse survival (Fig. 2a, b), decreased migration (Fig. 3a-c) and higher astrocytic 
differentiation (Fig. 4c) compared to those grown in conditioned medium collected from anti-
inflammatory microglia. The conditioned medium derived from different microglia 
phenotypes had similar influence on NSC proliferation (Fig. 2c) and neuronal or 
oligodendrocytic differentiation (Fig. 4a, b, d).  
Furthermore, utilizing qPCR we demonstrated NSCs differentiated in microglial conditioned 
media expressing increased level of the pro-inflammatory chemokine CCL2 compared to the 
control counterpart (Fig. 5a), and that was more notable when NSCs were grown in the pro-
inflammatory microglia conditioned medium. In summary, we found differentially polarized 
microglia impacts on NSCs functions distinctly. 
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The major findings of the present studies are listed as following. 
 Glioma cells inhibit microglial caspase-3 for their expansion and invasion 
 Glioma NOS2 activity induces S-nitrosylation of caspase-3 in microglia 
 S-nitrosylated caspase-3 accumulates in microglial mitochondria due to glioma- induced 
inhibition of thioredoxin-2 activity  
 Repression of glioma NOS2 reduces microglia recruitment and tumor expansion 
 Depletion of microglial Casp3 gene promotes glioma tumor growth   
 Microglial regulations on neural stem cells are dependent on their polarization states 
 
We uncovered a novel microglia-glioma cell-cell communication signaling pathway, wherein 
NO produced by NOS2 in glioma cells leads to an S-nitrosylation-dependent inhibition of 
Trx2 activity in microglial cells, which in turn results in increased S-nitrosylation and 
inhibition of caspase-3, an event which promotes the tumor-supportive polarization of 
microglia. Furthermore, appropriate mice models were used to validate glioma NOS2 and 
microglial caspase-3 as the upstream and downstream molecular components respectively of 
this signaling pathway. However, the signaling events in the downstream of caspase-3 remain 
unclear. It is worthy to investigate how microglial tumor-supportive phenotype is 
mechanistically induced when its caspase-3 activity is repressed below the basal level.  
 
Caspase-3 is constitutively expressed at a low level which has several non-apoptotic roles. 
The inhibition of caspase-3 likely has negative regulations on microglial pro-inflammatory 
functions. On the other hand, the accumulation of SNO-procaspase-3 might have positive 
regulations on microglial pro-tumoral phenotype independent of caspase catalytic activity. 
Then, the majority of procaspase-3 and SNO-procaspase-3 were found present in cytosolic 
fraction. Under the experimental condition, the level of mitochondrial SNO-procaspase-3 was 
increased, but the origin of that is elusive. The increased SNO-procaspase-3 is likely to be of 
mitochondria origin, although it could also be transported from the cytosol. Further studies 
are required to explore potential dynamics of cellular SNO-procaspase-3. Finally, Txnip is 
the endogenous inhibitor for Trx, and it is able to translocate to cellular compartments. To 
examine the level of Txnip can provide insight of additional inhibitory mechanisms on Trx2. 
It is assumed the level of Txnip decreases in cytosol but increases in mitochondria in 
microglia exposed to glioma cells.  
 
With respect to in vivo study, we generated a microglial caspase-3 knockout model which 
provided direct evidence for our hypothesis. The investigations can be extended as to 
determine the precise phenotype of glioma-associated microglia in both knockout mice and 
control group. This work can be conducted by utilizing conventional immunofluorescence 
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staining or by transcriptome profiling and analysis. Overall, these future studies could 
advance our understanding of mechanisms behind microglia-glioma cell communication 
system. On the other hand, within the niche microglia also cross-talk with NSCs and their 
influences on NSCs functions are dependent on polarization states. It is of interest to identify 
microglia-derived soluble factors that mediate the regulations on NSCs in future study. 
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